Type 2 Diabetes Mellitus (T2DM)DCMPNCT06939413
Diabetes Management Using Continuous Glucose Monitors and Remote Patient Monitoring in Underserved Populations
A study testing Continuous glucose monitor (CGM) in people with Type 2 Diabetes Mellitus (T2DM), run by Diabetes Solutions International at 1 site in United States.
Trial summary
The goal of this 52 week prospective study is to learn whether a Diabetes Care Management Program using a continuous glucose monitor (CGM) and remotely monitoring (RPM) glucose readings can help improve glucose levels and diabetes related distress in individuals with uncontrolled type 2 diabetes. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Type 2 Diabetes Mellitus (T2DM)
- What is being tested?
- Continuous glucose monitor (CGM)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 18 Mar 2025to Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults 18 years or older with Type 2 diabetes AND
- A1c > 8%
Who cannot join
- Pregnancy (participant-reported)
- Previous real time CGM use for more than 6 weeks in the last 3 months
- Use of steroids
- Active cancer treatment
- Terminal illness
- Dementia, mental impairment
- Type 1 diabetes
- End stage renal disease, on dialysis
Trial locations and contacts
1 site in 1 country.
United States1 site
Community Health Center of Franklin County
Greenfield, Massachusetts, 01301
About this study
Official title: Establishing a Sustainable Diabetes Care Management Program Using Continuous Glucose Monitors and Remote Patient Monitoring for Underserved Populations in Safety Net Clinics
The goal of this 52 week prospective study is to learn whether a Diabetes Care Management Program using a continuous glucose monitor (CGM) and remotely monitoring (RPM) glucose readings can help improve glucose levels and diabetes related distress in individuals with uncontrolled type 2 diabetes. The CGM and RPM are used as an adjunct to usual care.
The main questions it aims to answer are:
Read more
Does use of CGM \& RPM improve A1c? Does use of CGM \& RPM improve the percent of time spent with glucose levels between 70-180 mg/dl? Does the diabetes care management program improve diabetes related distress?
Participants enrolled in the study will be wearing a CGM. Participants will be able to see the glucose readings from the CGM and see how their glucose level responds to food, physical activity, medications and daily life.
The diabetes primary care team will be remotely monitoring the participant's glucose data from the CGM. They will reach out to the participant to make adjustments in treatment regimen as needed.
Participants will answer a "Problem Areas in Diabetes"questionnaire that asks questions about diabetes related distress.
Read the detailed description
BACKGROUND \& RATIONALE:
Medical Alumni Volunteer Expert Network (MAVEN) Project is a nonprofit organization dedicated to addressing social, racial, and economic inequities in the healthcare system through the power of telemedicine. The project recruits an experienced corps of volunteer medical specialists and connects them virtually with primary care providers (PCPs) at community health centers using a digital health platform. The services provided include medical consults, eConsults, mentoring, and Continuing Medical Education (CME) programs.
Patients with diabetes seen in safety net clinics are more complex with a higher incidence of diabetes related complications and other chronic conditions. PCPs are often overwhelmed and frustrated with managing diabetes in these patients, especially with the lack of glucose data. Continuous glucose monitor (CGM) use provides a complete glucose picture leading to appropriate adjustment in treatment regimen. In addition, individuals wearing a CGM are more likely to modify their physical activity and eating habits based on the real time glucose levels from the CGM.
MAVEN Project has been instrumental in enhancing diabetes management and improving patient outcomes in these safety net clinics, where 1 in 3 persons live in poverty and 63% identify as a racial/ethnic minority.
Given our early success, it became quite apparent that there was an opportunity to develop an evidence-based diabetes care management program incorporating CGM and remote patient monitoring (RPM) that would improve diabetes outcomes in the underserved population with a potential for implementation in other safety net clinics across the country. PCPs at front line clinics have access to endocrinology expertise through MAVEN Project. Remote patient monitoring of CGM data is now possible as over 98% of the FQHCs offer telehealth services as compared to 48 % in 2018.
PRIMARY OBJECTIVE:
To determine if a sustainable diabetes care management program incorporating CGM and RPM can improve glucose levels and diabetes related distress in individuals with diabetes seen at safety net clinics.
SECONDARY OBJECTIVE:
To determine if a sustainable diabetes care management program incorporating CGM and RPM can improve clinician and patient satisfaction.
STUDY DESIGN:
This is a single-arm prospective 24-week study with an optional 28 week extension designed to investigate the effect of a sustainable diabetes care management program incorporating CGM and RPM on improving glucose levels, diabetes related distress and patient satisfaction in individuals with diabetes seen at safety net clinics. PCP satisfaction will also be assessed. Patients from a clinic site not involved in the study will be used as case matched controls.
All eligible subjects will start on CGM \& RPM. Participants will use "guided experiments "during the first 7 to 10 days to understand the effects of food and physical activity on their glucose levels., Participants will follow up with the diabetes primary care team in 10-14 days to review the glucose data.
It is anticipated that about 20% of participants will require insulin and 80% will be on non-insulin treatment. Participants on insulin will continue real time CGM wear throughout the 52-week study. Participants not on insulin will wear real time CGM for the first 12 weeks and intermittently thereafter. All participants will be educated on the use of CGM to help manage their diabetes.
The RPM dashboard will be reviewed weekly, and outreach made to participants with low time in range 70-180 mg/dl (TIR) or no sensor data. CGM and RPM data will be used to adjust the treatment regimen.
CME will be provided by MAVEN Project on topics that are crucial for the PCPs to effectively manage diabetes. A PCP baseline educational needs assessment will be obtained to help guide the timing and necessity of the various CME sessions. Educational sessions will be provided for ancillary staff.
Endocrinology expertise will be provided through e-consults to MAVEN endocrinologists for specific patient management questions. MAVEN Endocrinologists will provide additional support through biweekly meetings with the clinic diabetes champion and monthly study site meetings.
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Being tested
- Continuous glucose monitor (CGM)
- Keywords
- Uncontrolled type 2 diabetes mellitus, CGM, Remote patient monitoring
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Continuous glucose monitor (CGM)Device
The glucose data from the CGM will help participants to understand the effect of lifestyle and medications on their glucose levels. The glucose levels from the CGM will be remotely monitored. Outreach will be made to participants not reaching glycemic goals. Appropriate adjustments in treatment regimen will be made based on the glucose data obtained from CGM and RPM
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Other | The participants will be in the intervention arm for 24 weeks with an optional 28 week extension . The intervention being studied is continuous glucose monitoring (CGM) and remote patient monitoring that is being provided as an adjunct to usual diabetes care Receives: Device: Continuous glucose monitor (CGM) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in A1c
A1c is a blood test that measures the average glucose level over the previous 2 to 3 months. A normal A1c is 5.7 to 6.4%. The usual goal for most people with diabetes is < 7% or as close to normal as possible without low glucose levels
Measured: Baseline, 12, 24, 36 and 52 weeks
Change in time in range (TIR)
TIR measures the percentage of glucose values between 70-180 mg/dl ie the percentage of time spent between 70-180 mg/dl . The usual goal for most individuals with diabetes is to have TIR > 70%
Measured: Baseline, 6, 12, 24, 36 and 52 weeks
Change in Problem Areas in Diabetes (PAID) score
PAID is a 20 point questionnaire that assesses diabetes related distress. A lower score indicates less diabetes related distress. A score of > 40 indicates significant diabetes related distress. Typically the PAID score decreases in response to diabetes care management. An extremely low score (0-10) combined with high glucose levels may be indicative of denial. The score can range from 0 to 125.
Measured: Baseline, 12, 24 and 52 weeks
Secondary outcomes (5)
Change in time above range (TAR)
TAR measure the percent of time with glucose levels > 180 mg/dl. The usual goal for diabetes is < 25%
Measured: Assessed at baseline, 6, 12, 24, 36 and 52 weeks
Change in time below range (TBR)
TBR measure the percent of time with glucose levels < 70 mg/dl. The usual goal for diabetes is < 4%
Measured: Assessed at baseline, 6, 12, 24, 36 and 52 weeks
Change in Glucose Management Indicator (GMI)
GMI provides an estimate of the A1c level based on the average glucose levels measured by a continuous glucose monitor (CGM) over the previous 14 days A normal GMI is 5.7 to 6.4% . The usual goal for diabetes is < 7% or as close to normal as possible without a low glucose
Measured: Assessed at baseline, 6, 12, 24, 36 and 52 weeks
Patient Satisfaction Survey
This is a survey that measures the patient's satisfaction with the diabetes care management program. The questions use a 5-point Likert scale with a higher score indicating satisfaction with the program . The score can range from 7 to 35.
Measured: Assessed at 12, 24 and 52 weeks
Change in Primary care provider (PCP) Satisfaction
The survey assesses the PCP satisfaction with how diabetes care is delivered in the clinic. The questions use a 5-point Likert scale with the score ranging from 5 to 15. A higher score indicates satisfaction with the program.
Measured: Assessed at baseline , 24 and 52 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2025
- Study start18 Mar 2025
- Primary completionNov 2026 (estimated)
- Study completionNov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 2 Diabetes Mellitus (T2DM)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Single-arm prospective 24-week study with an optional 28 week extension Patients from a clinic site not involved in the study will be used as case matched controls.
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Diabetes Solutions International
- Sponsor type
- University, hospital or other
- Collaborators
- DexCom, Inc., Tidepool, MAVEN Project
- Responsible party
- Sponsor
- Investigators
- Sushma Reddy, MD, Principal investigator, Diabetes Solutions International
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06939413
- Sponsor's protocol ID
- IIS-2024-172
- Acronym
- DCMP
- Status last verified
- Aug 2026
- First submitted
- 15 Apr 2025
- Last updated
- 17 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Establishing a Sustainable Diabetes Care Management Program Using Continuous Glucose Monitors and Remote Patient Monitoring for Underserved Populations in Safety Net Clinics
- ClinicalTrials.gov ID
- NCT06939413
- Acronym / sponsor ID
- DCMP / IIS-2024-172
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Keywords
- Uncontrolled type 2 diabetes mellitus, CGM, Remote patient monitoring
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Diabetes Solutions InternationalUniversity, hospital or other
- Collaborators
- DexCom, Inc., Tidepool, MAVEN Project
- Study start
- 18 Mar 2025 (actual)
- Primary completion
- Nov 2026 (estimated)
- Study completion
- Nov 2026 (estimated)
- First posted
- 22 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this 52 week prospective study is to learn whether a Diabetes Care Management Program using a continuous glucose monitor (CGM) and remotely monitoring (RPM) glucose readings can help improve glucose levels and diabetes related distress in individuals with uncontrolled type 2 diabetes. The CGM and RPM are used as an adjunct to usual care.
The main questions it aims to answer are:
Does use of CGM \& RPM improve A1c? Does use of CGM \& RPM improve the percent of time spent with glucose levels between 70-180 mg/dl? Does the diabetes care management program improve diabetes related distress?
Participants enrolled in the study will be wearing a CGM. Participants will be able to see the glucose readings from the CGM and see how their glucose level responds to food, physical activity, medications and daily life.
The diabetes primary care team will be remotely monitoring the participant's glucose data from the CGM. They will reach out to the participant to make adjustments in treatment regimen as needed.
Participants will answer a "Problem Areas in Diabetes"questionnaire that asks questions about diabetes related distress.
Detailed description
BACKGROUND \& RATIONALE:
Medical Alumni Volunteer Expert Network (MAVEN) Project is a nonprofit organization dedicated to addressing social, racial, and economic inequities in the healthcare system through the power of telemedicine. The project recruits an experienced corps of volunteer medical specialists and connects them virtually with primary care providers (PCPs) at community health centers using a digital health platform. The services provided include medical consults, eConsults, mentoring, and Continuing Medical Education (CME) programs.
Patients with diabetes seen in safety net clinics are more complex with a higher incidence of diabetes related complications and other chronic conditions. PCPs are often overwhelmed and frustrated with managing diabetes in these patients, especially with the lack of glucose data. Continuous glucose monitor (CGM) use provides a complete glucose picture leading to appropriate adjustment in treatment regimen. In addition, individuals wearing a CGM are more likely to modify their physical activity and eating habits based on the real time glucose levels from the CGM.
MAVEN Project has been instrumental in enhancing diabetes management and improving patient outcomes in these safety net clinics, where 1 in 3 persons live in poverty and 63% identify as a racial/ethnic minority.
Given our early success, it became quite apparent that there was an opportunity to develop an evidence-based diabetes care management program incorporating CGM and remote patient monitoring (RPM) that would improve diabetes outcomes in the underserved population with a potential for implementation in other safety net clinics across the country. PCPs at front line clinics have access to endocrinology expertise through MAVEN Project. Remote patient monitoring of CGM data is now possible as over 98% of the FQHCs offer telehealth services as compared to 48 % in 2018.
PRIMARY OBJECTIVE:
To determine if a sustainable diabetes care management program incorporating CGM and RPM can improve glucose levels and diabetes related distress in individuals with diabetes seen at safety net clinics.
SECONDARY OBJECTIVE:
To determine if a sustainable diabetes care management program incorporating CGM and RPM can improve clinician and patient satisfaction.
STUDY DESIGN:
This is a single-arm prospective 24-week study with an optional 28 week extension designed to investigate the effect of a sustainable diabetes care management program incorporating CGM and RPM on improving glucose levels, diabetes related distress and patient satisfaction in individuals with diabetes seen at safety net clinics. PCP satisfaction will also be assessed. Patients from a clinic site not involved in the study will be used as case matched controls.
All eligible subjects will start on CGM \& RPM. Participants will use "guided experiments "during the first 7 to 10 days to understand the effects of food and physical activity on their glucose levels., Participants will follow up with the diabetes primary care team in 10-14 days to review the glucose data.
It is anticipated that about 20% of participants will require insulin and 80% will be on non-insulin treatment. Participants on insulin will continue real time CGM wear throughout the 52-week study. Participants not on insulin will wear real time CGM for the first 12 weeks and intermittently thereafter. All participants will be educated on the use of CGM to help manage their diabetes.
The RPM dashboard will be reviewed weekly, and outreach made to participants with low time in range 70-180 mg/dl (TIR) or no sensor data. CGM and RPM data will be used to adjust the treatment regimen.
CME will be provided by MAVEN Project on topics that are crucial for the PCPs to effectively manage diabetes. A PCP baseline educational needs assessment will be obtained to help guide the timing and necessity of the various CME sessions. Educational sessions will be provided for ancillary staff.
Endocrinology expertise will be provided through e-consults to MAVEN endocrinologists for specific patient management questions. MAVEN Endocrinologists will provide additional support through biweekly meetings with the clinic diabetes champion and monthly study site meetings.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Single-arm prospective 24-week study with an optional 28 week extension Patients from a clinic site not involved in the study will be used as case matched controls.
| Arm | Type | Receives |
|---|---|---|
| Intervention | Other | Device: Continuous glucose monitor (CGM)The participants will be in the intervention arm for 24 weeks with an optional 28 week extension . The intervention being studied is continuous glucose monitoring (CGM) and remote patient monitoring that is being provided as an adjunct to usual diabetes care |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Adults 18 years or older with Type 2 diabetes AND
- A1c > 8%
Key exclusion criteria (8 listed)
- Pregnancy (participant-reported)
- Previous real time CGM use for more than 6 weeks in the last 3 months
- Use of steroids
- Active cancer treatment
- Terminal illness
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Continuous glucose monitor (CGM)The glucose data from the CGM will help participants to understand the effect of lifestyle and medications on their glucose levels. The glucose levels from the CGM will be remotely monitored. Outreach will be made to participants not reaching glycemic goals. Appropriate adjustments in treatment regimen will be made based on the glucose data obtained from CGM and RPM | Device | Intervention |
Primary outcome
Change in A1c
Time frame: Baseline, 12, 24, 36 and 52 weeks
A1c is a blood test that measures the average glucose level over the previous 2 to 3 months. A normal A1c is 5.7 to 6.4%. The usual goal for most people with diabetes is < 7% or as close to normal as possible without low glucose levels
Change in time in range (TIR)
Time frame: Baseline, 6, 12, 24, 36 and 52 weeks
TIR measures the percentage of glucose values between 70-180 mg/dl ie the percentage of time spent between 70-180 mg/dl . The usual goal for most individuals with diabetes is to have TIR > 70%
Change in Problem Areas in Diabetes (PAID) score
Time frame: Baseline, 12, 24 and 52 weeks
PAID is a 20 point questionnaire that assesses diabetes related distress. A lower score indicates less diabetes related distress. A score of > 40 indicates significant diabetes related distress. Typically the PAID score decreases in response to diabetes care management. An extremely low score (0-10) combined with high glucose levels may be indicative of denial. The score can range from 0 to 125.
5 secondary outcomes
Change in time above range (TAR)
Time frame: Assessed at baseline, 6, 12, 24, 36 and 52 weeks
Change in time below range (TBR)
Time frame: Assessed at baseline, 6, 12, 24, 36 and 52 weeks
Change in Glucose Management Indicator (GMI)
Time frame: Assessed at baseline, 6, 12, 24, 36 and 52 weeks
Patient Satisfaction Survey
Time frame: Assessed at 12, 24 and 52 weeks
Change in Primary care provider (PCP) Satisfaction
Time frame: Assessed at baseline , 24 and 52 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Type 2 Diabetes Mellitus (T2DM)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 2
A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes
RecruitingPhase 3
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
Obesity, Overweight
RecruitingObservational study
Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes
T2DM (Type 2 Diabetes Mellitus)
Active, not recruitingObservational study
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sushma Reddy, MD principal investigator
Diabetes Solutions International
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Continuous glucose monitor (CGM) in people with Type 2 Diabetes Mellitus (T2DM), run by Diabetes Solutions International at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 17 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in A1c (time frame: Baseline, 12, 24, 36 and 52 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2026.